TY - JOUR
T1 - Human umbilical cord tissue-derived mesenchymal stromal cells as adjuvant therapy for myocardial infarction
T2 - a review of current evidence focusing on pre-clinical large animal models and early human trials
AU - Raposo, Luís
AU - Lourenço, André P.
AU - Nascimento, Diana S.
AU - Cerqueira, Rui
AU - Cardim, Nuno
AU - Leite-Moreira, Adelino
N1 - Publisher Copyright:
© 2021 International Society for Cell & Gene Therapy
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Although biologically appealing, the concept of tissue regeneration underlying first- and second-generation cell therapies has failed to translate into consistent results in clinical trials. Several types of cells from different origins have been tested in pre-clinical models and in patients with acute myocardial infarction (AMI). Mesenchymal stromal cells (MSCs) have gained attention because of their potential for immune modulation and ability to promote endogenous tissue repair, mainly through their secretome. MSCs can be easily obtained from several human tissues, the umbilical cord being the most abundant source, and further expanded in culture, making them attractive as an allogeneic “of-the-shelf” cell product, suitable for the AMI setting. The available evidence concerning umbilical cord-derived MSCs in AMI is reviewed, focusing on large animal pre-clinical studies and early human trials. Molecular and cellular mechanisms as well as current limitations and possible translational solutions are also discussed.
AB - Although biologically appealing, the concept of tissue regeneration underlying first- and second-generation cell therapies has failed to translate into consistent results in clinical trials. Several types of cells from different origins have been tested in pre-clinical models and in patients with acute myocardial infarction (AMI). Mesenchymal stromal cells (MSCs) have gained attention because of their potential for immune modulation and ability to promote endogenous tissue repair, mainly through their secretome. MSCs can be easily obtained from several human tissues, the umbilical cord being the most abundant source, and further expanded in culture, making them attractive as an allogeneic “of-the-shelf” cell product, suitable for the AMI setting. The available evidence concerning umbilical cord-derived MSCs in AMI is reviewed, focusing on large animal pre-clinical studies and early human trials. Molecular and cellular mechanisms as well as current limitations and possible translational solutions are also discussed.
KW - cell therapy
KW - mesenchymal stromal/stem cells
KW - MSCs
KW - myocardial infarction
KW - regenerative medicine
KW - umbilical cord
KW - Wharton's jelly
UR - http://www.scopus.com/inward/record.url?scp=85107431875&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2021.05.002
DO - 10.1016/j.jcyt.2021.05.002
M3 - Review article
AN - SCOPUS:85107431875
SN - 1465-3249
VL - 23
SP - 974
EP - 979
JO - Cytotherapy
JF - Cytotherapy
IS - 11
ER -